Syndax Pharmaceuticals In... (SNDX)

The mean of analysts' price targets for Syndax (SNDX) points to a 158.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

Shares of Syndax Pharmaceuticals are still down 45% over the past three years. The Q2 report was encouraging on multiple fronts with a strong start for the Revuforj launch in KMT2A AML and Niktimvo la...

Syndax Pharmaceuticals just delivered strong second quarter results, beating expectations, and management also increased its long-term market opportunity projections. Both Revuforj and Niktimvo are dr...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Keith Alan Goldan - CFO, Treasurer & Chief Accounting Officer Michael A. Met...

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.8 per share a year ago.

Syndax (SNDX) Q2 Revenue Jumps 986%

Syndax (SNDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 237.8% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positi...

Syndax now has two approved therapies—NIKTIMVO and Revuforj—but the share price remains under pressure despite these milestones. NIKTIMVO faces a crowded cGVHD market and skepticism about its commerci...